Toronto, Ontario–(Newsfile Corp. – March 30, 2021) – Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) (FSE: 9DF) (“Mindset” or the “Company“), a drug discovery and development company focused on developing next generation psilocybin and N,N-Dimethyltryptamine (DMT) inspired medicines and related technologies, is pleased to announce that it has expanded its scientific leadership team with the appointment of Dr. Malik Slassi as Senior Vice President of Innovation in a full time capacity and the appointment of Mr. Ian Dean as Director of Preclinical Development.
As an originating member of Mindset’s Scientific Advisory Board, Dr. Slassi is the architect of the Company’s portfolio of novel and differentiated psychedelic drug families, along with the Company’s patent pending psilocybin synthesis process. Dr. Slassi has over 30 years of experience in successful identification and development of small molecule drug candidates across multiple therapeutic areas and a record of numerous successes in medicinal chemistry, with approximately 24 drugs advanced into late-stage preclinical development, clinical development, and introduction into the pharmaceutical market. Prior to joining Mindset, Dr. Slassi was Senior Vice President of Discovery Research at Trillium Therapeutics Inc., which he joined following the successful sale to Trillium Therapeutics Inc. of Fluorinov Pharma Inc., a medicinal chemistry platform company of which Dr. Slassi was the founder, President and Chief Scientific Officer. Dr. Slassi holds a Ph.D. in Chemistry from the University of Claude Bernard, Lyon, France. He completed his postdoctoral work in the Chemistry Department at the University of Montreal, Canada, and has held management and scientific leadership positions with several recognized multinational pharmaceutical companies.
Dr. Slassi commented: “Mindset is one of the few truly innovative discovery research and development engines in the emerging medical psychedelic field, which represents a promising potential commercial opportunity in the treatment of mental health disorders. I am pleased to contribute to our leadership team as we focus on strengthening Mindset’s patent portfolio of novel products. Mindset’s strategy of maximizing the value of its pipeline through clinical validation has the potential to transform the patient journey in managing a range of mental health indications.”
James Lanthier, Chief Executive Officer of Mindset, commented: “We are thrilled to have Dr. Slassi join Mindset on a full-time basis. Malik’s insights into drug design and medicinal chemistry as they apply to the serotonergic system and the central nervous system are formidable and given the timing of our innovations, Mindset is well positioned to continue to play a pioneering role in developing next generation, novel psychedelic medications.
Additionally, Mindset is pleased to welcome Ian Dean as Director, Preclinical Development. Ian is a seasoned toxicologist and pharmacology professional with over 40 years of intensive expertise in drug development. Mr. Dean has served in the roles of VP Business Development and Toxicology as well as Chief Scientific Officer for several organizations providing investigational new drug-enabling and clinical development services to global pharmaceutical clients. Mr. Dean is a Diplomate of the American Board of Toxicology and the Institute of Biology in Toxicology as well as a European Registered Toxicologist. Mr. Dean will assist Mindset in advancing its lead compounds through investigational new drug-enabling studies into clinical programs.”
FOR MORE INFORMATION, PLEASE CONTACT:
James Lanthier
CEO
jlanthier@mindsetpharma.com
Jason Atkinson
VP, Corporate Development
jatkinson@mindsetpharma.com
647-938-5266
About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds. www.mindsetpharma.com
Forward-Looking Information
This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change, unless required by law. The reader is cautioned not to place undue reliance on forward-looking information.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.